Current Editions
How Alphamab is differentiating in crowded cancer targets
The Suzhou biotech outlines its rationale for designing bispecific ADCs with lower antibody-drug
Product Development
Product Development
Early signals stack up: Two small molecules activate GCase in Parkinson’s
Gain reports GCase substrate reduction in CNS; Vanqua shows peripheral enzyme activation plus CNS penetration
Finance
Stelios Papadopoulos brings the long view on biotech on The BioCentury Show
Company building, pricing pressure, innovation from China, and the future of big pharmas
Third Rock backs Steve Paul’s latest schizophrenia spinout in $165M round: Venture Report
Plus: Ambros, Atavistik raise megarounds; MBX’s fund addressing chronic diseases; and more
BioCentury ISSN 1097-7201